NRXP

Over the past six months, NRx Pharmaceuticals experienced several stock-impacting events. The Q1 2026 earnings release (May 18, 2026) reported an EPS of -0.040 USD, highlighting an anticipated FDA decision on the ANDA for Preservative-Free Ketamine in Q3 2026, initiation of commercial manufacturing, and FDA acceptance of an IND for NRX-101 as an adjunct to robotic-enabled TMS. The Q2 2026 earnings release (August 17, 2026) reported an EPS of -0.440 USD, with significant earnings and revenue surprises. Positive news included the FDA reclassifying a major amendment to a minor one for preservative-free ketamine (September 15, 2026), indicating no major drug-related deficiencies, and the award of European Patent Rights for GNK-301 (September 14, 2026). HOPE Therapeutics began deploying Zeta Surgical's FDA-Cleared Robotic TMS System (September 11, 2026), and NRx Defense Systems received an $11.18 million DARPA prime contract (September 30, 2026) to evaluate Robotic Magnetic Stimulation with NRX-101. Despite these positive developments, the stock price decreased by 17.77% in the month leading up to October 5, 2026, and by 12.23% over the last year, with a year-to-date return of 5.90%. As of October 6, 2026, the share price was $2.94, representing a 19.89% decline over the past year.